1 Industry Outlook
1.1 Industry Overview
1.2 Industry Trends
1.2.1 R&D Pipeline in the Pharmaceutical Industry
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market
3.3 Trends in the Biologics Market
3.4 Related Markets
3.4.1 Over-the-counter Drugs
3.4.2 Orphan Drugs
3.4.3 Human Insulin
4 Market Outlook
4.1 Market segmentation
4.2 PEST Analysis
4.3 Porter 5(Five) Forces
5 Market Characteristics
5.1 DRO Analysis – Market Dynamics
5.1.1 Drivers
5.1.1.1 Growing incidence of disease across the globe
5.1.1.2 Increasing number of biologics approvals
5.1.2 Opportunities
5.1.2.1 Strong portfolio of product pipeline and huge number of ongoing clinical trials
5.1.2.2 Increasing opportunities in emerging markets
5.1.3 Restraints
5.1.3.1 Challenges associated with biologics production
5.1.3.2 Increasing number of biologics going off patent and emergence of biosimilars
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
6 Products: Market Size and Analysis
6.1 Overview
6.2 Monoclonal Antibodies
6.3 Recombinant Proteins/Hormones
6.4 Vaccines
6.5 Cell & Gene Therapy
6.6 Others
7 Applications: Market Size and Analysis
7.1 Overview
7.2 Cancer
7.3 Immunological Disorders
7.4 Infectious Disease
7.5 Hematologic Disorders
7.6 Cardiovascular Disease
7.7 Others
8 Regions: Market Size and Analysis
8.1 Overview
8.2 North America
8.2.1 US
8.2.2 Canada
8.3 Europe
8.3.1 UK
8.3.2 Germany
8.3.3 France
8.3.4 Spain
8.4 Asia Pacific
8.4.1 India
8.4.2 China
8.4.3 Japan
8.5 Rest of the World
9 Competitive Landscape
10 Vendors Profile
10.1 F. Hoffmann-La Roche
10.1.1 Overview
10.1.2 Business Units
10.1.3 Geographic Presence
10.1.4 Business Focus
10.1.5 SWOT Analysis
10.1.6 Business Strategies
10.2 Sanofi S.A.
10.2.1 Overview
10.2.2 Business Units
10.2.3 Geographic Presence
10.2.4 Business Focus
10.2.5 SWOT Analysis
10.2.6 Business Strategies
10.3 Amgen Inc.
10.3.1 Overview
10.3.2 Geographic Presence
10.3.3 Business Focus
10.3.4 SWOT Analysis
10.3.5 Business Strategies
10.4 Novo Nordisk A/S
10.4.1 Overview
10.4.2 Business Units
10.4.3 Geographic Presence
10.4.4 Business Focus
10.4.5 SWOT Analysis
10.4.6 Business Strategies
10.5 AbbVie Inc.
10.5.1 Overview
10.5.2 Geographic Presence
10.5.3 Business Focus
10.5.4 SWOT Analysis
10.5.5 Business Strategies
10.6 Johnson & Johnson
10.6.1 Overview
10.6.2 Business Units
10.6.3 Geographic Revenue
10.6.4 Business Focus
10.6.5 SWOT Analysis
10.6.6 Business Strategies
10.7 Novartis AG
10.7.1 Overview
10.7.2 Business Units
10.7.3 Geographic Revenue
10.7.4 Business Focus
10.7.5 SWOT Analysis
10.7.6 Business Strategies
11 Companies to Watch for
11.1 Bristol–Myers Squibb
11.1.1 Overview
11.2 GlaxoSmithKline plc
11.2.1 Overview
11.3 Merck & Co.
11.3.1 Overview
11.4 Eli Lilly and Company Ltd.
11.4.1 Overview
11.5 Teva Pharmaceutical Industries Ltd.
11.5.1 Overview
11.6 AstraZeneca PLC
11.6.1 Overview
11.7 Takeda Pharmaceuticals
11.7.1 Overview
Annexure
Abbreviations